Strong Sovaldi Sales Prompt Plans To Decry Price

By John Wilkerson / July 23, 2014 at 7:58 PM
Gilead announced Wednesday (July 23) that it sold $3.48 billion of its breakthrough hepatitis C drug Sovaldi in the second quarter of this year, beating Wall Street expectations, and the company is on track to generate between $21 billion and $23 billion in sales from all its drugs this year -- prompting health plans and the National Coalition on Health Care to decry the $84,000-per-course cost of Sovaldi and demand Gilead lower the price. Many believe the public-shaming campaign by...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.